Skip to content

Can a Non invasive Gentle Brain Stimulation Restore the Heart Function and Balance in Diabetic patients with Nerve Problems?

The efficacy of Transcranial direct current stimulation on cardiac autonomic function and balance in patients with diabetic autonomic neuropathy - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085567
Enrollment
26
Registered
2025-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: Transcranial Direct Current Stimulation: Active stimulation for 20 minutes at 2mA intensity along with Balance exercises Control Intervention1: Transcranial Direct Current Stimulation:

Sponsors

Manav rachna international institute of research and studies
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus for more than five years,Diabetic patients with features of cardiac autonomic dysfunction such as unexplained tachycardia, orthostatic hypotension, and poor exercise tolerance ,or with other symptoms of autonomic dysfunction, MNSI Score more than 2, SDNN Value less than 50, RMSSD Value less than 25, and LF-HF ratio more than 1, ,HbA1C equal or more than 9%

Exclusion criteria

Exclusion criteria: Vascular complications (venous or arterial ulcers) Patients with Hypersensitive skin, skin allergies or skin infections History or evidence of cardiovascular disease (history of angina, shortness of breath, uncontrolled hypertension). History or evidence of neurological disorder (i.e. hemiparesis, myelopathy, cerebellar ataxia etc) Significant musculoskeletal deformity (amputation, scoliosis, severe osteoarthritis). Lower extremity arthritis that limits standing or weight bearing position. Patients with cancer Patients taking insulin injections

Design outcomes

Primary

MeasureTime frame
Heart rate variability (HRV) - LF, HF, LF/HF, RMSSD, SDNN Timed up and go test (TUG) Berg balance scale scoreTimepoint: At baseline(Day1), after 3 weeks and after 6 weeks

Secondary

MeasureTime frame
Michigan neuropathy screening instrument scoreTimepoint: At baseline(Day1), after 3 weeks & after 6 weeks

Countries

India

Contacts

Public ContactDr Sunita Kumari

Manav Rachna International Institute of Research and Studies

aparna8482@gmail.com8800577022

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026